| 摘要 |
<p>PPARg agonistic medicinal compositions containing a hydroxylated derivative of a highly unsaturated fatty acid having a C20-22 carbon chain or a pharmaceutically acceptable salt thereof, preferably PPARϜ agonistic medicinal compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof; and use of these PPARϜ agonistic compositions in treating circulatory diseases, arteriosclerosis, lipid metabolic diseases, diabetes and inflammatory diseases.</p> |
